FDA
-
-
-
-
-
-
-
Adagene to Participate in Two Upcoming Investor Conferences
-
-
-
-
-
-
-
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable
-
-
-
-
-
-
-
Adagene Provides Business Update and 2026 Objectives
-
-
-
-
-
-
-
Adagene Inc (ADAG) PT Lowered to $7 at H.C. Wainwright
-
-
-
-
-
-
-
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further
-
-
-
-
-
-
-
Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
After-Hours Movers 11/29: (CPIX) (ADAG) (OM) Higher; (LIZI) (INTU) Lower (more...)
-
330,674 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

